Capital Group Companies Inc Form 8.3 - Pfizer Inc. (3817G)
20 Novembro 2015 - 9:55AM
UK Regulatory
TIDMPFZ
RNS Number : 3817G
Capital Group Companies Inc
20 November 2015
FORM 8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997,
TAKEOVER RULES, 2013
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES
REPRESENTING 1% OR MORE
1. KEY INFORMATION
Name of person dealing The Capital Group
(Note 1) Companies, Inc.
====================== =====================
Company dealt in Pfizer Inc.
====================== =====================
Class of relevant US$0.05 common stock
security to which (ISIN: US7170811035)
the dealings being
disclosed relate
(Note 2)
====================== =====================
Date of dealing 19 November 2015
====================== =====================
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the
class of relevant security dealt in (Note 3)
Long Short
====================== ================= ===================
Number (%) Number (%)
====================== ========= ====== =========== ======
(1) Relevant 128,980,819
securities (2.0895%)
====================== ================= ===================
(2) Derivatives
(other than options)
====================== ================= ===================
(3) Options and
agreements to
purchase/sell
====================== ================= ===================
128,980,819*
Total (2.0895%)
====================== ================= ===================
(b) Interests and short positions in relevant securities of the
company, other than the class dealt in (Note 3)
Class of relevant Long Short
security:
============================ =================== =====================
Number (%) Number (%)
============================ ========= ====== =========== ======
(1) Relevant securities
============================ =================== =====================
(2) Derivatives (other
than options)
============================ =================== =====================
(3) Options and agreements
to purchase/sell
============================ =================== =====================
Total
============================ =================== =====================
2. DEALINGS (Note 4)
(a) Purchases and sales
Purchase/sale Number of relevant Price per
securities unit (Note
5)
=============== =========================== ================
Sale 1,680,137 USD - 32.186
=============== =========================== ================
Sale 1,000,000 USD - 32.265
=============== =========================== ================
Sale 942,332 USD - 32.237
=============== =========================== ================
Sale 762,391 USD - 32.321
=============== =========================== ================
Sale 719,384 USD - 32.054
=============== =========================== ================
Sale 533,696 USD - 32.619
=============== =========================== ================
Sale 514,881 USD - 32.308
=============== =========================== ================
Sale 306,733 USD - 32.345
=============== =========================== ================
Sale 250,284 USD - 32.865
=============== =========================== ================
Sale 237,900 USD - 32.160
=============== =========================== ================
Sale 163,796 USD - 32.367
=============== =========================== ================
Sale 156,061 USD - 32.350
=============== =========================== ================
Sale 52,900 USD - 32.322
=============== =========================== ================
Sale 39,261 USD - 32.389
=============== =========================== ================
Sale 18,800 USD - 32.343
=============== =========================== ================
Sale 13,633 USD - 32.480
=============== =========================== ================
Sale 10,600 USD - 32.463
=============== =========================== ================
Sale 6,068 USD - 32.363
=============== =========================== ================
Purchase 1,300 USD - 32.649
=============== =========================== ================
(b) Derivatives transactions (other than options transactions)
Product Nature of Number of relevant Price
name, transaction securities per unit
e.g. CFD (Note 6) (Note 7) (Note
5)
========= ============ ================== ==========
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product Writing, Number Exercise Type, Expiry Option
name, selling, of securities price e.g. date money
e.g. purchasing, to which American, paid/received
call varying the option European per unit
option etc. relates etc. (Note
(Note 5)
7)
======= ============ ============== ======== ========== ====== ==============
(ii) Exercising
Product name, Number of securities Exercise price
e.g. call per unit (Note
option 5)
============= =========================== ===================
(d) Other dealings (including transactions in respect of new securities) (Note 4)
Nature of Details Price per
transaction unit
(Note 8) (if applicable)
(Note 5)
============ ============== ====================
3. OTHER INFORMATION
Agreements, arrangements or understandings relating to options
or derivatives
Full details of any agreement, arrangement or understanding
between the person disclosing and any other person relating to the
voting rights of any relevant securities under any option referred
to on this form or relating to the voting rights or future
acquisition or disposal of any
relevant securities to which any derivative referred to on this
form is referenced. If none,
this should be stated.
Is a Supplemental Form 8 attached? (Note 9) NO
Date of disclosure 19 November 2015
=========================== ===================
Contact name Christopher Aquino
=========================== ===================
Telephone number +213.615.0469
=========================== ===================
If a connected EFM, n/a
name of offeree/offeror
with which connected
=========================== ===================
If a connected EFM, n/a
state nature of connection
(Note 10)
=========================== ===================
Y
*53 US$0.05 common stock due to a transfer in.
This information is provided by RNS
The company news service from the London Stock Exchange
END
ISEEAEFEADDSFEF
(END) Dow Jones Newswires
November 20, 2015 06:55 ET (11:55 GMT)
Pfizer (LSE:PFZ)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025
Pfizer (LSE:PFZ)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025
